<DOC>
	<DOC>NCT00520598</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison to GARDASIL (TM)</brief_summary>
	<brief_title>Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Female between 16 to 26 years old Has never had Pap testing or have only had normal Pap test results Lifetime history of 0 to 4 sexual partners History of an abnormal cervical biopsy result; History of a positive test for HPV; History of external genital/vaginal warts; Currently a user of any illegal drugs or an alcohol abuser History of severe allergic reaction that required medical attention Are pregnant Received a marketed HPV vaccine Currently enrolled in a clinical trial Currently has (or has a history of) certain medical conditions or is currently taking or has taken certain medications (details will be discussed at time of consent)</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>